Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 28.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | ort on Form 8-K/A (“Amendment No. 1”) amends Item 5.02 of the Company’s Current Report on Form 8-K filed on March 3, 202 |
| 28.03.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | forth by specific reference in such a filing. Item 5.02. Departure of Directors or Certain Officers; Election of Directo |
Stammdaten
Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.
Unternehmen & Branche
| Name | Whitehawk Therapeutics, Inc. |
|---|---|
| Ticker | WHWK |
| CIK | 0001422142 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 197,8 Mio. USD |
| Beta | 0,62 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 7,145,000 | -20,596,000 | -0.33 | 150,830,000 | 136,311,000 |
| 2025-09-30 | 10-Q | 0 | -17,746,000 | -0.26 | 167,017,000 | 157,168,000 |
| 2025-06-30 | 10-Q | 0 | -52,615,000 | -0.76 | 180,822,000 | 172,066,000 |
| 2025-03-31 | 10-Q | 7,145,000 | 73,016,000 | 1.83 | 234,002,000 | 221,728,000 |
| 2024-12-31 | 10-K | 25,983,000 | -63,691,000 | -2.36 | 70,319,000 | 52,478,000 |
| 2024-09-30 | 10-Q | 7,212,000 | -12,546,000 | -0.46 | 85,698,000 | 68,868,000 |
| 2024-06-30 | 10-Q | 6,179,000 | -14,583,000 | -0.54 | 101,620,000 | 78,791,000 |
| 2024-03-31 | 10-Q | 5,353,000 | -18,289,000 | -0.68 | 111,073,000 | 90,460,000 |
| 2023-12-31 | 10-K | 24,354,000 | -65,765,000 | -2.44 | 132,423,000 | 105,195,000 |
| 2023-09-30 | 10-Q | 5,959,000 | -16,302,000 | -0.60 | 139,659,000 | 118,196,000 |
| 2023-06-30 | 10-Q | 6,202,000 | -17,971,000 | -0.67 | 151,228,000 | 131,419,000 |
| 2023-03-31 | 10-Q | 5,867,000 | -15,223,000 | -0.57 | 170,654,000 | 145,986,000 |
| 2022-12-31 | 10-K | 15,216,000 | -60,513,000 | -2.69 | 184,237,000 | 158,378,000 |
| 2022-09-30 | 10-Q | 4,245,000 | -14,474,000 | -0.68 | 194,103,000 | 169,108,000 |
| 2022-06-30 | 10-Q | 3,437,000 | -18,269,000 | -0.87 | 128,636,000 | 108,730,000 |
| 2022-03-31 | 10-Q | 2,307,000 | -13,857,000 | -0.66 | 142,319,000 | 124,628,000 |
| 2021-12-31 | 10-Q | 14,000,000 | 157,910,000 | 136,406,000 | ||
| 2021-12-31 | 10-K | 14,000,000 | -110,090,000 | -12.41 | 157,910,000 | 136,406,000 |
| 2021-09-30 | 10-Q | 0 | -87,088,000 | -9.17 | 168,772,000 | 150,925,000 |
| 2021-06-30 | 10-Q | 0 | -1,536,000 | -0.60 | 37,424,041 | -19,369,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Giacobello Scott M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -141,600 | 4.13 | -584,808.00 | -381,8% | |
| 2026-04-15 | Giacobello Scott M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -77,000 | 3.86 | -297,220.00 | -194,0% | |
| 2026-04-14 | BALL BRYAN | Officer, See remarks | Open Market Sale | -92,460 | 3.64 | -336,554.40 | -219,7% | |
| 2026-04-13 | BALL BRYAN | Officer, See remarks | Open Market Sale | -26,389 | 3.46 | -91,305.94 | -59,6% | |
| 2026-04-10 | BALL BRYAN | Officer, See remarks | Open Market Sale | -6,596 | 3.43 | -22,624.28 | -14,8% | |
| 2026-04-09 | BALL BRYAN | Officer, See remarks | Open Market Sale | -50,000 | 3.57 | -178,500.00 | -116,5% | |
| 2026-04-09 | Lennon David James | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -14,500 | 3.38 | -49,010.00 | -32,0% | |
| 2026-04-02 | Lennon David James | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -26,858 | 3.48 | -93,465.84 | -61,0% | |
| 2026-03-02 | BALL BRYAN | Officer, See remarks | Open Market Sale | -1,834 | 3.31 | -6,069.81 | -4,0% | |
| 2026-03-02 | Lennon David James | Director, Officer, CHIEF EXECUTIVE OFFICER | Open Market Sale | -5,100 | 3.31 | -16,878.96 | -11,0% | |
| 2026-03-02 | Giacobello Scott M. | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -2,594 | 3.31 | -8,585.10 | -5,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.